Neogen Corporation (NEOG)vsNovartis AG ADR (NVS)
NEOG
Neogen Corporation
$11.78
+0.08%
HEALTHCARE · Cap: $2.60B
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6413% more annual revenue ($56.69B vs $870.40M). NVS leads profitability with a 22.5% profit margin vs -0.9%. NEOG appears more attractively valued with a PEG of 0.66. NVS earns a higher WallStSmart Score of 51/100 (C-).
NEOG
Hold41
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.7%
Fair Value
$55.73
Current Price
$11.78
$43.95 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Operating margin of 1.4%
ROE of -29.0% — below average capital efficiency
Revenue declined 0.1%
Earnings declined 85.6%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NEOG
The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : NEOG
The primary concerns for NEOG are Operating Margin, Return on Equity, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
NEOG profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
NEOG carries more volatility with a beta of 1.76 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 41/100), backed by strong 22.5% margins. NEOG offers better value entry with a 80.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neogen Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?